By InvitationNot Applicable

24-h Energy Expenditure and Anti-obesity Medication

Italy30 participantsStarted 2025-07-01

Plain-language summary

This study investigates the long-term effects of anti-obesity medications (Semaglutide and Tirzepatide) on energy metabolism (24-hour energy expenditure and substrate oxidation) and body composition via Dual-energy X-ray absorptiometry (DXA)

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Body mass index (BMI) \>= 30 kg/m² or \>= 27 kg/m² with at least one weight-related comorbidity and stable body weight (±2 kg in prior 3 months) * informed consent, adherence to study protocol, negative pregnancy test and contraception use (if applicable), and absence of cardiovascular events or end-organ damage. Exclusion Criteria: * psychiatric conditions impairing adherence, history of medullary thyroid cancer, pregnancy/lactation * diabetes

What they're measuring

change in 24h energy expenditure after 6 months of treatment

Timeframe: Baseline and 6 months after treatment initiation

Trial details

NCT IDNCT07041983

SponsorUniversity of Pisa

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-06-01

View on ClinicalTrials.gov More Obesity trials